In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly ...

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

RSV, and norovirus are spreading at high levels in the U.S., causing overlapping symptoms like fever, fatigue, and nausea.

designed to protect against RSV and COVID-19. Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

"Medidata is at the forefront of a critical shift in the life sciences sector," said Anthony Costello, CEO, Medidata. "By harnessing AI-powered solutions and partnering with visionaries, we aren't ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

HOSPITALS have been hit by a “highly infectious” winter vomiting bug which experts have warned you can catch more than once. Norovirus cases are continuing to soar with new NHS data ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza ... while a triple shot that also adds in respiratory syncytial virus (RSV) should also reach the clinic ...